Cell Therapy in Veterinary Medicine as a Proof-of-Concept for Human Therapies: Perspectives From the North American Veterinary Regenerative Medicine Association

Arzi, Boaz; Webb, Tracy L.; Koch, Thomas; Volk, Susan W.; Betts, Dean H.; Watts, Ashlee E.; Goodrich, Laurie R.; Kallos, Michael S.; Kol, Amir

doi:10.3389/fvets.2021.779109

Cited by 13 publications

(7 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs hold great potential in veterinary regenerative medicine. The recent scientific literature supports the feasibility and safety of delivering stem cells in a clinical setting, thus justifying the expansion of their clinical use in recent years [ 28 ]. Setting up a proper protocol for cells’ transportation to the administration site is one of the most delicate phases in managing MSC therapy.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stromal Cells Derived from Canine Adipose Tissue: Evaluation of the Effect of Different Shipping Vehicles Used for Clinical Administration

Andreoli,

Berni,

Conti

et al. 2024

IJMS

View full text Add to dashboard Cite

Mesenchymal Stromal Cells (MSCs)-based therapies are rapidly gaining interest in veterinary medicine. Cellular therapy represents a new challenge for practitioners and requires precise coordination between the cell processing laboratory and the veterinary clinic. Cryopreservation is the best method to provide fast, in-time, and long-distance delivery of cells for therapeutic applications. However, potentially toxic cryoprotectants and xenobiotic products make the direct administration of cells impracticable for patients. Alternatively, the cells may be resuspended in a ready-to-use vehicle and shipped to the veterinary clinic. In this study, two nutrient-poor vehicles (physiologic saline and ringer lactate solutions) and two nutrient-rich vehicles (the releasate derived from autologous Platelet Poor Plasma and Platelet Rich Plasma) were tested on adipose tissue-derived canine MSCs (AD-MSCs). AD-MSCs stored for 2, 4, or 24 h in the different media were compared regarding mortality, metabolic activity, and replicative capacity. Furthermore, antioxidant activity and the pattern of expression of genes related to AD-MSCs function were performed following 24 h of storage. The results showed that all the different vehicles preserve cell vitality and replication following short-term storage. In long-term storage, the vehicle and cell density affect cell vitality, proliferation, and gene expression (CCL-2, CXCR-4, and TSG-6). Nutrient-rich vehicles seem better suited to preserve cell functionalities in this contest.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stromal Cells Derived from Canine Adipose Tissue: Evaluation of the Effect of Different Shipping Vehicles Used for Clinical Administration

Andreoli,

Berni,

Conti

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…The use of equine‐derived MSCs reduces the cost compared with the development of human MSC bioreactor processes where the cell source is scarcer and more valuable and often expensive serum‐free media is used. Additionally, the use of the equine MSCs in this study can be applied to human health, as several publications have discussed the translation between companion animal models and humans (Arzi et al, 2021; Kol et al, 2015). The pipeline for approval for animal treatments is much more streamlined, requiring significantly less time and money (Fürdös et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

Bioprocess development for cord blood mesenchymal stromal cells on microcarriers in Vertical‐Wheel bioreactors

Roberts,

Lepage,

Koch

et al. 2023

Biotech & Bioengineering

Self Cite

View full text Add to dashboard Cite

Equine mesenchymal stromal cells (MSCs) have been found to be beneficial for the treatment of many ailments, including orthopedic injuries, due to their superior differentiation potential and immunomodulating properties. Cell therapies require large cell numbers, which are not efficiently generated using conventional static expansion methods. Expansion of equine cord blood‐derived MSCs (eCB‐MSCs) in bioreactors, using microcarriers as an attachment surface, has the potential to generate large numbers of cells with increased reproducibility and homogeneity compared with static T‐flask expansion. This study investigated the development of an expansion process using Vertical‐Wheel (VW) bioreactors, a single‐use bioreactor technology that incorporates a wheel instead of an impeller. Initially, microcarriers were screened at small scale to assess eCB‐MSC attachment and growth and then in bioreactors to assess cell expansion and harvesting. The effect of different donors, serial passaging, and batch versus fed batch were all examined in 0.1 L VW bioreactors. The use of VW bioreactors with an appropriate microcarrier was shown to be able to produce cell densities of up to 1E6 cells/mL, while maintaining cell phenotype and functionality, thus demonstrating great potential for the use of these bioreactors to produce large cell numbers for cell therapies.

show abstract

“…Specifically for regenerative medicine, there is also known variability in cell function between species. 30,43 These limitations are difficult to overcome.…”

Section: Challenges Of a One-health Approach In Regenerative Medicinementioning

confidence: 99%

The oromaxillofacial region as a model for a one-health approach in regenerative medicine

Arzi

Nolta

Vapniarsky

2022

ajvr

Self Cite

View full text Add to dashboard Cite

The concept of a one-health approach in regenerative medicine has gained tremendous momentum in the scientific and public communities in recent years. Knowledge derived from this approach informs innovative biomedical research, clinical trials, and practice. The ultimate goal is to translate regenerative strategies for curing diseases and improving the quality of life in animals and people. Building and fostering strong and enthusiastic interdisciplinary and transdisciplinary collaboration between teams with a wide range of expertise and backgrounds is the cornerstone to the success of the one-health approach and translational sciences. The veterinarian’s role in conducting clinical trials in client-owned animals with naturally occurring diseases is critical and unique as it may potentially inform human clinical trials. The veterinary regenerative medicine and surgery field is on a steep trajectory of discoveries and innovations. This manuscript focuses on oromaxillofacial-region regeneration to exemplify how the concept of interdisciplinary and transdisciplinary collaboration and the one-health approach influenced the authors’ work experience at the University of California-Davis.

show abstract

Cell Therapy in Veterinary Medicine as a Proof-of-Concept for Human Therapies: Perspectives From the North American Veterinary Regenerative Medicine Association

Cited by 13 publications

References 74 publications

Mesenchymal Stromal Cells Derived from Canine Adipose Tissue: Evaluation of the Effect of Different Shipping Vehicles Used for Clinical Administration

Mesenchymal Stromal Cells Derived from Canine Adipose Tissue: Evaluation of the Effect of Different Shipping Vehicles Used for Clinical Administration

Bioprocess development for cord blood mesenchymal stromal cells on microcarriers in Vertical‐Wheel bioreactors

The oromaxillofacial region as a model for a one-health approach in regenerative medicine

Contact Info

Product

Resources

About